<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835547</url>
  </required_header>
  <id_info>
    <org_study_id>D50841</org_study_id>
    <nct_id>NCT02835547</nct_id>
  </id_info>
  <brief_title>Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN)</brief_title>
  <acronym>CARMIN</acronym>
  <official_title>Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that chronic inflammatory dysimmune state promotes the development of&#xD;
      cardiovascular complications. The biological assumption is based on the fact that chronic&#xD;
      inflammation promotes lesions of the vessel wall (endothelial alterations, calcification,&#xD;
      atherosclerosis). The clinical aim is to allow to identify high-risk patients and to act in&#xD;
      prevention.&#xD;
&#xD;
      The project CARMIN involves the assessment of cardiovascular risk factors, their management,&#xD;
      and their influence on cardiovascular prognosis in patients with autoimmune diseases and&#xD;
      immunodeficiencies acquired. It is based on the creation and monitoring of a cohort of&#xD;
      patients with different types of dysimmune disorders: systemic lupus erythematosus,&#xD;
      rheumatoid arthritis, psoriasis, scleroderma, systemic vasculitis ANCA, kidney transplants,&#xD;
      and hematopoietic stem cells transplants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of any cardiovascular event (will be recorded from the patient files and/or phone calls to patient&quot;)</measure>
    <time_frame>2 years</time_frame>
    <description>The cardiovascular events : cardiovascular death, myocardial infarction, stroke, peripheral arterial disease, ischemic manifestations in other territories, heart failure, arrhythmia, deep vein thrombosis or pulmonary embolism.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Inflammatory and Acquired Dysimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Systemic lupus erythematosus</arm_group_label>
    <description>Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <description>Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriasis</arm_group_label>
    <description>Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Scleroderma</arm_group_label>
    <description>Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hematopoietic stem cells transplants</arm_group_label>
    <description>Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney transplants</arm_group_label>
    <description>Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)</description>
    <arm_group_label>Hematopoietic stem cells transplants</arm_group_label>
    <arm_group_label>Kidney transplants</arm_group_label>
    <arm_group_label>Psoriasis</arm_group_label>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <arm_group_label>Scleroderma</arm_group_label>
    <arm_group_label>Systemic lupus erythematosus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma,&#xD;
        kidney transplants, or hematopoietic stem cells transplants&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients followed in the various services of medical specialties pole of the Edouard&#xD;
             Herriot hospital&#xD;
&#xD;
          -  The diagnosis of the pathology selected for this study based on a clear clinical and&#xD;
             biological evaluation supported by criteria specific to each pathology and compatible&#xD;
             with international standards.&#xD;
&#xD;
          -  Date of diagnosis should not be less than 5 years (+/- 1 year), except for scleroderma&#xD;
             patients where it has been extended to 10 years.&#xD;
&#xD;
          -  For kidney transplant patients the investigators take into account only patients with&#xD;
             a maximum of 2 years of dialysis before graft.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetic patients&#xD;
&#xD;
          -  HIV seropositive&#xD;
&#xD;
          -  Patients with multiple pathologies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular event</keyword>
  <keyword>risk factors</keyword>
  <keyword>inflammatory diseases and acquired dysimmune</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

